Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

IGC Pharma (IGC) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Pharma (IGC) over the last 16 years, with Q3 2025 value amounting to -$0.02.

  • Pharma's EPS (Basic) changed 0.0% to -$0.02 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.07, marking a year-over-year increase of 6111.11%. This contributed to the annual value of -$0.09 for FY2025, which is 5769.81% up from last year.
  • Per Pharma's latest filing, its EPS (Basic) stood at -$0.02 for Q3 2025, which was down 0.0% from -$0.02 recorded in Q2 2025.
  • In the past 5 years, Pharma's EPS (Basic) registered a high of -$0.02 during Q1 2025, and its lowest value of -$0.09 during Q4 2023.
  • Moreover, its 4-year median value for EPS (Basic) was -$0.04 (2021), whereas its average is -$0.04.
  • Its EPS (Basic) has fluctuated over the past 5 years, first tumbled by 11742.21% in 2021, then skyrocketed by 7777.78% in 2024.
  • Quarter analysis of 4 years shows Pharma's EPS (Basic) stood at -$0.05 in 2021, then crashed by 92.98% to -$0.09 in 2023, then skyrocketed by 77.78% to -$0.02 in 2024, then changed by 0.0% to -$0.02 in 2025.
  • Its EPS (Basic) was -$0.02 in Q3 2025, compared to -$0.02 in Q2 2025 and -$0.02 in Q1 2025.